The present invention describes tetracyclic compounds of formula (IA) or (IB),
wherein the symbols R, X, A, Y, R2, R3 and D are as defined in the specification, their use in the treatment of certain diseases, e.g. depending on MK-2 or TNF activity, and ways of manufacturing them.
The present invention describes tetracyclic compounds of formula (IA) or (IB),
wherein the symbols R, X, A, Y, R2, R3 and D are as defined in the specification, their use in the treatment of certain diseases, e.g. depending on MK-2 or TNF activity, and ways of manufacturing them.
An ingenious strategy is for the first time proposed to develop solution-processable deep-blue HLCT emitters by attaching rigid imide aliphatic rings onto the HLCT emitting core. With outstanding characteristics of these emitters, the unprecedented OLED performances with a record-breaking efficiency of 11.5 % and high colour purity are achieved, showing competitive superiority for ultrahigh-definition
The present technology relates to stabilizing additives and electrolytes containing the same for use in electrochemical devices such as lithium ion batteries and capacitors. The stabilizing additives include triazinane triones and bicyclic compounds comprising succinic anhydride, such as compounds of Formulas I and II described herein.